Ravulizumab
alexion pharma
['emergent ']
93.1% of participants with aqp4 and #nmosd who received #ravulizumab reported treatment-emergent adverse events. #neurotwitter #aanam 
Neurology Advisor provides health care professionals with comprehensive information and clinical news on the management of neurological conditions.